Unknown

Dataset Information

0

Generation of therapeutic protein variants with the human serum albumin binding capacity via site-specific fatty acid conjugation.


ABSTRACT: Extension of the serum half-life is an important issue in developing new therapeutic proteins and expanding applications of existing therapeutic proteins. Conjugation of fatty acid, a natural human serum albumin ligand, to a therapeutic protein/peptide was developed as a technique to extend the serum half-life in vivo by taking advantages of unusually long serum half-life of human serum albumin (HSA). However, for broad applications of fatty acid-conjugation, several issues should be addressed, including a poor solubility of fatty acid and a substantial loss in the therapeutic activity. Therefore, herein we systematically investigate the conditions and components in conjugation of fatty acid to a therapeutic protein resulting in the HSA binding capacity without compromising therapeutic activities. By examining the crystal structure and performing dye conjugation assay, two sites (W160 and D112) of urate oxidase (Uox), a model therapeutic protein, were selected as sites for fatty acid-conjugation. Combination of site-specific incorporation of a clickable p-azido-L-phenylalanine to Uox and strain-promoted azide-alkyne cycloaddition allowed the conjugation of fatty acid (palmitic acid analog) to Uox with the HSA binding capacity and retained enzyme activity. Deoxycholic acid, a strong detergent, greatly enhanced the conjugation yield likely due to the enhanced solubility of palmitic acid analog.

SUBMITTER: Cho J 

PROVIDER: S-EPMC5740134 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Generation of therapeutic protein variants with the human serum albumin binding capacity via site-specific fatty acid conjugation.

Cho Jinhwan J   Lim Sung In SI   Yang Byung Seop BS   Hahn Young S YS   Kwon Inchan I  

Scientific reports 20171221 1


Extension of the serum half-life is an important issue in developing new therapeutic proteins and expanding applications of existing therapeutic proteins. Conjugation of fatty acid, a natural human serum albumin ligand, to a therapeutic protein/peptide was developed as a technique to extend the serum half-life in vivo by taking advantages of unusually long serum half-life of human serum albumin (HSA). However, for broad applications of fatty acid-conjugation, several issues should be addressed,  ...[more]

Similar Datasets

| S-EPMC10996255 | biostudies-literature
| S-EPMC6532450 | biostudies-literature
| S-EPMC5367151 | biostudies-literature
| S-EPMC7175456 | biostudies-literature
| S-EPMC7238188 | biostudies-literature
| S-EPMC4701599 | biostudies-literature
| S-EPMC2596408 | biostudies-literature
| S-EPMC6349961 | biostudies-literature
| S-EPMC3483484 | biostudies-literature
| S-EPMC3073228 | biostudies-literature